Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

442
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
442
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.7K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.9K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Angina IV: Management01:26

Angina IV: Management

487
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
487
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.9K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex differences in photon-counting computed tomography findings across hypertrophic phenotypes.

European heart journal. Imaging methods and practice·2026
Same author

Genomic and proteogenomic insights into Spontaneous Coronary Artery Dissection (SCAD): A systematic review of emerging multi-omic evidence.

Vascular pharmacology·2026
Same author

Functional Assessment of Hypertrophic Phenotype Cardiomyopathies Using Combined Cardiopulmonary Exercise Testing and Echocardiography: A Pilot Single-Centre Study.

Journal of clinical medicine·2026
Same author

Cardiac magnetic resonance-derived left atrioventricular coupling index predicts outcome in reduced ejection fraction.

ESC heart failure·2026
Same author

CarDiac magnEtic resonance for prophylactic implantable cardioVerter defibrillAtor ThErapy in ischemic dilated CardioMyopathy: Prognostic implication of papillary muscles involvement.

Progress in cardiovascular diseases·2026
Same author

Myocardial infarction with non-obstructive coronary arteries: a pathway to achieve guideline adherence.

Heart (British Cardiac Society)·2026

Related Experiment Video

Updated: Apr 27, 2026

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.0K

Pharmacological approaches to coronary microvascular dysfunction.

Giacinta Guarini1, Alda Huqi1, Doralisa Morrone1

  • 1Cardiovascular Medicine Division, Cardio-Thoracic and Vascular Department, University of Pisa, Italy.

Pharmacology & Therapeutics
|July 9, 2014
PubMed
Summary
This summary is machine-generated.

Coronary microvascular dysfunction impacts various cardiovascular conditions. This review explores pharmacological treatments for microvascular dysfunction in patients with heart disease, hypertension, obesity, and diabetes.

Keywords:
CardiomyopathiesCoronary microvascular dysfunctionDiabetesIschemic heart diseaseNo-reflowReactive oxygen species

More Related Videos

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
07:53

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter

Published on: June 16, 2022

3.3K
Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
08:35

Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction

Published on: August 17, 2022

3.0K

Related Experiment Videos

Last Updated: Apr 27, 2026

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
08:21

Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations

Published on: July 21, 2023

2.0K
Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter
07:53

Standardized Rat Coronary Ring Preparation and Real-Time Recording of Dynamic Tension Changes Along Vessel Diameter

Published on: June 16, 2022

3.3K
Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction
08:35

Oxygenation-sensitive Cardiac MRI with Vasoactive Breathing Maneuvers for the Non-invasive Assessment of Coronary Microvascular Dysfunction

Published on: August 17, 2022

3.0K

Area of Science:

  • Cardiology
  • Pharmacology
  • Pathophysiology

Background:

  • Coronary microvascular dysfunction is increasingly recognized as a key factor in cardiovascular diseases.
  • Abnormalities are observed in acute myocardial infarction, angina, cardiomyopathies, hypertension, obesity, and diabetes.
  • Understanding the pathophysiology is crucial for effective treatment.

Purpose of the Study:

  • To review the pathophysiological basis of coronary microvascular dysfunction.
  • To examine current and emerging pharmacological strategies for managing this condition.
  • To provide insights into treatment across diverse clinical contexts.

Main Methods:

  • Literature review of pathophysiological mechanisms.
  • Analysis of established and novel pharmacological agents.
  • Synthesis of data relevant to clinical applications.

Main Results:

  • Detailed examination of pathophysiological information relevant to treatment.
  • Coverage of existing drugs and new agents, including preclinical data.
  • Discussion of pharmacological approaches in various cardiovascular conditions.

Conclusions:

  • Pharmacological interventions are essential for managing coronary microvascular dysfunction.
  • A comprehensive understanding of pathophysiology guides treatment selection.
  • Further research into novel agents holds promise for improved patient outcomes.